MDV3100
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer, Hormone Refractory Prostate Cancer
Trial Timeline
Jul 23, 2007 → Apr 2, 2018
NCT ID
NCT00510718About MDV3100
MDV3100 is a phase 1 stage product being developed by Astellas Pharma for Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00510718. Target conditions include Prostate Cancer, Hormone Refractory Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01606982 | Pre-clinical | Completed |
| NCT01911741 | Phase 1 | Completed |
| NCT01565928 | Phase 1 | Completed |
| NCT01901133 | Phase 1 | Completed |
| NCT01911715 | Phase 1 | Completed |
| NCT01284920 | Phase 1/2 | Completed |
| NCT00510718 | Phase 1 | Completed |
Competing Products
20 competing products in Prostate Cancer